Cochrane · systematic review · CD011093
Fulvestrant for hormone‐sensitive metastatic breast cancer
Lee, CI, Goodwin, A, Wilcken, N · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
Breast CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 14.3%High 6 · 85.7%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Fulvestrant versus other endocrine treatment
Population: women with hormone‐sensitive advanced breast cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Time to progression Fulvestrant vs other endocrine treatment | HR 0.95 [0.89, 1.02] | 9 studies · 4258 participants | Moderate Downgraded: imprecision, inconsistency |
Clinical benefit rate Fulvestrant vs other endocrine treatment | RR 1.03 [0.97, 1.1] | 9 studies · 4105 participants | High |
Mortality Fulvestrant vs other endocrine treatment | HR 0.97 [0.87, 1.09] | 5 studies · 2480 participants | High |
Vasomotor toxicity Fulvestrant vs other endocrine treatment | RR 1.02 [0.89, 1.18] | 8 studies · 3544 participants | High |
Arthralgia Fulvestrant vs other endocrine treatment | RR 0.96 [0.86, 1.09] | 7 studies · 3244 participants | High |
Gynaecological toxicity Fulvestrant vs other endocrine treatment | RR 1.22 [0.94, 1.57] | 6 studies · 2848 participants | High |
Quality of life Fulvestrant vs other endocrine treatment | no estimate extracted | 4 studies · 4 participants | High |